HC Wainwright Issues Negative Estimate for MLTX Earnings

Key Points

• HC Wainwright lowered MoonLake Immunotherapeutics’ Q3 2026 earnings estimate to a loss of $0.70 per share from $0.62, while maintaining a Buy rating and $50 price target.
• Analyst sentiment is mixed: the stock has a consensus Hold rating and average price target of $24.57, despite ten Buy, four Hold, and three Sell ratings.
• MoonLake recently reported a quarterly loss of $0.84 per share, beating consensus estimates of a $0.91 loss; shares opened at $16.47 and remain well below their 52-week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at HC Wainwright cut their Q3 2026 earnings estimates for MoonLake Immunotherapeutics in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.70) per share for the quarter, down from their prior estimate of ($0.62). HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics' Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.76) EPS and FY2027 earnings at ($2.67) EPS.

MLTX has been the topic of a number of other reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a research report on Friday, August 7th. Needham & Company LLC lifted their price target on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, May 12th. Leerink Partners increased their price objective on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an "outperform" rating in a research note on Wednesday, July 1st. Finally, BTIG Research reissued a "buy" rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $24.57.

MoonLake Immunotherapeutics Stock Performance

MLTX opened at $16.47 on Monday. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75. The stock has a market cap of $1.40 billion, a P/E ratio of -4.29 and a beta of 1.06. The stock's 50 day simple moving average is $18.91 and its 200 day simple moving average is $17.91. The company has a debt-to-equity ratio of 0.23, a current ratio of 12.56 and a quick ratio of 12.56.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.07.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 68,289 shares of MoonLake Immunotherapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the sale, the chief executive officer owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of the business's stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.43, for a total transaction of $971,500.00. Following the completion of the transaction, the insider directly owned 2,824,551 shares of the company's stock, valued at $54,881,025.93. The trade was a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 344,800 shares of company stock valued at $6,820,071 in the last three months. 10.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several hedge funds have recently modified their holdings of MLTX. Geode Capital Management LLC increased its position in MoonLake Immunotherapeutics by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company's stock worth $2,809,000 after purchasing an additional 559 shares in the last quarter. Squarepoint Ops LLC lifted its position in MoonLake Immunotherapeutics by 3.7% during the second quarter. Squarepoint Ops LLC now owns 17,571 shares of the company's stock valued at $829,000 after buying an additional 629 shares in the last quarter. Axiom Investors LLC DE grew its stake in MoonLake Immunotherapeutics by 3.2% during the fourth quarter. Axiom Investors LLC DE now owns 25,998 shares of the company's stock worth $343,000 after buying an additional 818 shares during the period. Russell Investments Group Ltd. grew its stake in MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock worth $45,000 after buying an additional 1,069 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company's stock worth $52,000 after buying an additional 1,158 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source